Sunday, June 18, 2023 8:07:48 AM
Is this audio only?
No hankmanhub. Here is the recorded video version: https://www.bizvod.com/program-group/program/8e4f3b2c3df701709b2cd8f1f89b3c05
Starts around min.9
Northwest Biotherapeutics, The Glimpse Group, INmune Bio, & Expion360
Jun 14, 2023
1h 0m
Sully and Mike Costa talk to Les Goldman, Senior VP/General Counsel of Northwest Biotherapeutics. He talks with them about the development of cancer vaccines that will help with solid tumors. They talk with Lyron Bentovim, Pres/CEO of The Glimpse Group about how VR can help businesses from marketing to hospitals. Sully talks with RJ Tesi, CEO of INmune Bio about upcoming technology that will help cancer and Alzheimer's patients. And Brian Schaffner, CEO of Expion360 about lithium batteries taking over the typical battery. Air Date 6/13/23
INmune Bio
Raymond J. Tesi, MD
CEO/CMO
Dr. Tesi - President, Chief Executive Officer and acting Chief Medical Officer
Professor Mark Lowdell, PhD
CSO/CMO
Prof. Lowdell - Chief Scientific Officer and Chief Manufacturing Officer.
J. Kelly Ganjei
Mr. Ganjei has been a director since September, 2016. (former Chief Executive Officer of Cognate BioService)
Linda Powers and Toucan Capital
https://www.secform4.com/filings/1711754/0001104659-20-008253.htm
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
